| Inca Minerals Limited (ICG) ORDINARY FULLY PAID |
Materials |
- |
Notification regarding unquoted securities - ICG
|
27 May 2025 11:19AM |
$0.005 |
$0.014 |
risen by
180%
|
|
| The a2 Milk Company Limited (A2M) ORDINARY FULLY PAID |
Consumer Staple |
$7,131 |
Ceasing to be a substantial holder
|
27 May 2025 11:02AM |
$8.355 |
$9.830 |
risen by
17.66%
|
|
| 4DMedical Limited (4DX) ORDINARY FULLY PAID |
Health Care |
$2,415 |
Investor Presentation - FDA Submission for CTVQ
|
27 May 2025 10:57AM |
$0.300 |
$4.220 |
risen by
1,306.67%
|
|
4DX - Price-sensitive ASX Announcement
Full Release
Key Points
- 4DMedical Limited has submitted its Computed Tomography Ventilation Quantification (CT VQ) product for FDA approval.
- The CT VQ product addresses significant unmet needs in lung diagnostics by providing functional imaging that quantifies regional ventilation using standard CT scans.
- The technology offers advantages over traditional imaging methods, including improved sensitivity and no requirement for contrast agents.
- The US market presents a large opportunity, with significant demand for advanced respiratory diagnostic solutions.
- Clinical validation studies have demonstrated the efficacy and safety of CT VQ, supporting its FDA submission.
- The company has outlined a reimbursement strategy to facilitate rapid market adoption, leveraging existing CPT codes and engaging with payers and providers.
- Commercialisation plans focus on the US healthcare system initially, with strategies for international market expansion.
- Strategic partnerships and collaborations with leading hospitals and research institutions underpin the product’s clinical integration.
- 4DMedical’s CT VQ is positioned to transform the landscape of respiratory diagnostics and offer substantial clinical and economic benefits.
- Key milestones include successful pre-submission meetings with the FDA, completion of validation studies, and an anticipated timeline for market entry.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| NAOS Ex-50 Opportunities Company Limited (NAC) ORDINARY FULLY PAID |
Financials |
$30 |
Change of Director's Interest Notice - S Evans
|
27 May 2025 10:48AM |
$0.440 |
$0.660 |
risen by
50%
|
|
| IVE Group Limited (IGL) ORDINARY FULLY PAID |
Communication Services |
$463 |
Bell Potter Emerging Leaders Conference Presentation
|
27 May 2025 10:40AM |
$2.580 |
$3.010 |
risen by
16.67%
|
|
| Loyal Lithium Limited (LLI) ORDINARY FULLY PAID |
Materials |
- |
Pause in Trading
|
27 May 2025 10:39AM |
$0.130 |
$0.130 |
fallen by
0%
|
|
| Kina Securities Limited (KSL) ORDINARY FULLY PAID |
Financials |
$381 |
Resignation of Group Chief Risk Officer, Philip Keller
|
27 May 2025 10:38AM |
$1.140 |
$1.300 |
risen by
14.04%
|
|
| Dotz Nano Limited (DTZ) ORDINARY FULLY PAID |
Information Technology |
$21 |
Cleansing Statement
|
27 May 2025 10:32AM |
$0.053 |
$0.031 |
fallen by
41.51%
|
|
| Hastings Technology Metals Limited (HAS) ORDINARY FULLY PAID |
Materials |
$111 |
Proposed issue of securities - HAS
|
27 May 2025 10:29AM |
$0.315 |
$0.500 |
risen by
58.73%
|
|
| Hastings Technology Metals Limited (HAS) ORDINARY FULLY PAID |
Materials |
$111 |
Acquisition of Whiteheads Gold project
|
27 May 2025 10:28AM |
$0.315 |
$0.500 |
risen by
58.73%
|
|
HAS - Price-sensitive ASX Announcement
Full Release
Key Points
- Hastings Technology Metals Limited has entered into a binding agreement to acquire the Whiteheads Gold Project from Evolution Mining Limited.
- The Whiteheads Gold Project is located near Kalgoorlie, Western Australia, and is prospective for gold and other commodities.
- Upfront and deferred payments are part of the transaction, along with a net smelter royalty on future production.
- The acquisition is consistent with Hastings’ strategy to diversify and grow its asset base beyond rare earths.
- Hastings plans to undertake exploration and development activities at Whiteheads to unlock value.
- The acquisition complements Hastings’ existing Yangibana Rare Earths Project.
- The company aims to utilize its technical expertise and infrastructure to advance Whiteheads.
- The transaction is expected to deliver value creation opportunities for Hastings shareholders.
- The announcement was made on 7 June 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dotz Nano Limited (DTZ) ORDINARY FULLY PAID |
Information Technology |
$21 |
Application for quotation of securities - DTZ
|
27 May 2025 10:25AM |
$0.056 |
$0.031 |
fallen by
44.64%
|
|
| Aspermont Limited (ASP) ORDINARY FULLY PAID |
Communication Services |
$23 |
Proposed issue of securities - ASP
|
27 May 2025 10:25AM |
$0.005 |
$0.008 |
risen by
60%
|
|
| Gratifii Limited (GTI) ORDINARY FULLY PAID |
Information Technology |
$33 |
Proposed issue of securities - GTI
|
27 May 2025 10:24AM |
$0.100 |
$0.076 |
fallen by
24%
|
|
| Gratifii Limited (GTI) ORDINARY FULLY PAID |
Information Technology |
$33 |
Proposed issue of securities - GTI
|
27 May 2025 10:24AM |
$0.100 |
$0.076 |
fallen by
24%
|
|
| Gratifii Limited (GTI) ORDINARY FULLY PAID |
Information Technology |
$33 |
Gratifii Completes Capital Raise
|
27 May 2025 10:23AM |
$0.100 |
$0.076 |
fallen by
24%
|
|
GTI - Price-sensitive ASX Announcement
Full Release
Key Points
- Gratifii Limited (GTI) completed a capital raise.
- The raise included participation from new and existing institutional and sophisticated investors.
- The capital raised will strengthen the company's balance sheet.
- Funds will support the development of GTI’s digital loyalty and rewards platform.
- The raise provides additional working capital for the company.
- Proceeds will help accelerate strategic growth initiatives.
- GTI expressed thanks to its investors for ongoing support.
- The raise is seen as vital for continued business development and innovation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Adelong Gold Limited (ADG) ORDINARY FULLY PAID |
Materials |
$24 |
Results of Meeting
|
27 May 2025 10:23AM |
$0.008 |
$0.009 |
risen by
12.50%
|
|
| Holista Colltech Limited (HCT) ORDINARY FULLY PAID |
Consumer Staple |
$26 |
Update on Collagen Business
|
27 May 2025 10:22AM |
$0.053 |
$0.070 |
risen by
32.08%
|
|
| Elementos Limited (ELT) ORDINARY FULLY PAID |
Materials |
$193 |
Change in substantial holding
|
27 May 2025 10:21AM |
$0.110 |
$0.445 |
risen by
304.55%
|
|
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$1,744 |
AGM Chair Address & CEO Presentation
|
27 May 2025 10:19AM |
$13.800 |
$13.770 |
fallen by
0.22%
|
|
NEU - Price-sensitive ASX Announcement
Full Release
Key Points
- DAYBUEâ„¢ (trofinetide) was approved by the FDA and launched in the US for Rett syndrome, generating significant revenue and royalties.
- Neuren received $142 million in cash from Acadia in 2023, with further milestone payments and royalties expected from increased US sales.
- The company completed two Phase 2 trials for NNZ-2591 in Phelan-McDermid syndrome (PMS) and Angelman syndrome (AS), with positive preliminary results reported.
- Enrollment is underway for Phase 2 trials of NNZ-2591 in Pitt Hopkins syndrome (PTHS) and FOXG1 syndrome, with results expected in Q4 2024.
- Neuren maintains a strong cash position ($127 million as of May 2024) with no debt, supporting an expanded pipeline and future growth.
- Global development for trofinetide in Rett syndrome is advancing, with Acadia and Neuren working on regulatory submissions in Europe and Japan.
- The company is actively engaging with FDA and other agencies on potential Phase 3 studies and other clinical trial design matters for NNZ-2591.
- Neuren’s strategic focus remains on rare neurological diseases, with the goal of bringing urgently needed therapies to market and maximizing value for shareholders.
- The Board and management are committed to advancing the late-stage clinical development pipeline and maintaining prudent financial management.
- Shareholders were thanked for their ongoing support and confidence in the company’s mission and growth trajectory.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bravura Solutions Limited (BVS) ORDINARY FULLY PAID |
Information Technology |
$915 |
Change of Director's Interest Notice
|
27 May 2025 10:18AM |
$2.150 |
$2.040 |
fallen by
5.12%
|
|
| Chorus Limited (CNU) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Communication Services |
$3,454 |
Revised indicative Initial Margin range - Capital Notes
|
27 May 2025 10:14AM |
$7.410 |
$7.960 |
risen by
7.42%
|
|
| EQ Resources Limited (EQR) ORDINARY FULLY PAID |
Materials |
$1,635 |
Response to ASX Appendix 3Y Query
|
27 May 2025 10:13AM |
$0.036 |
$0.340 |
risen by
844.44%
|
|
| Platinum Capital Limited (PMC) ORDINARY FULLY PAID |
Financials |
$449 |
Weekly Net Tangible Asset Backing
|
27 May 2025 10:10AM |
$1.370 |
$1.765 |
risen by
28.83%
|
|
| Platinum Asia Investments Limited (PAI) ORDINARY FULLY PAID |
Financials |
- |
Weekly Net Tangible Asset Backing
|
27 May 2025 10:09AM |
$1.050 |
$0.970 |
fallen by
7.62%
|
|
| Galan Lithium Limited (GLN) ORDINARY FULLY PAID |
Materials |
$520 |
Revised Investor Presentation
|
27 May 2025 10:08AM |
$0.099 |
$0.420 |
risen by
324.24%
|
|